Mark Corrigan

Mark Corrigan, M.D., is the co-founder and CEO of Tremeau Pharmaceuticals, a company advancing novel solutions for patients with acute and chronic pain. Prior to founding Tremeau, he held several executive positions at Zalicus, Sepracor, and Pharmacia Corp. Dr. Corrigan has led discovery and development efforts of multiple novel therapeutic approaches and has raised substantial capital through public markets to fund research, development, and company operations. Dr. Corrigan has held board roles at a number of public biopharmaceutical companies including Novelion, Cubist, and Avanir Pharmaceuticals. Dr. Corrigan is board certified in psychiatry and neurology. He received a medical degree from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.